Hantz Financial Services Inc. Sells 113 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Hantz Financial Services Inc. decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% during the third quarter, HoldingsChannel reports. The institutional investor owned 6,938 shares of the company’s stock after selling 113 shares during the period. Hantz Financial Services Inc.’s holdings in IDEXX Laboratories were worth $3,505,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Ridgewood Investments LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at $27,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at $28,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC increased its stake in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new position in IDEXX Laboratories in the 2nd quarter worth about $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDXX stock opened at $421.75 on Friday. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The firm has a market cap of $34.53 billion, a price-to-earnings ratio of 40.67, a PEG ratio of 3.68 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The firm has a 50-day simple moving average of $451.91 and a two-hundred day simple moving average of $477.81.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.53 earnings per share. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IDXX shares. Barclays reduced their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Piper Sandler reiterated a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. JPMorgan Chase & Co. cut their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $552.38.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.